Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Investigating the basis of immune-related adverse events caused by checkpoint inhibitor immunotherapy

FY 2022-23

Summary
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, achieving remarkably durable responses in a subset of patients. By blocking various cell surface molecules that inhibit immune cell function, ICIs potentiate tumour-reactive T cells to target neoplastic cells for elimination. Certain T cell receptors (TCRs) enable the specific recognition of tumour antigens, which encompass both self-derived antigens that can also be present in normal host tissues, as well as mutation-derived neoantigens that are seen as foreign by the immune system. While self-reactive T cells are typically restrained by immune tolerance mechanisms to avoid autoimmunity, these pathways can be obstructed by ICI-mediated disruption of inhibitory signals. Attesting to this breakdown in tolerance is the observation that patients treated with ICIs commonly experience immune-related adverse events (irAEs). These toxicities are unpredictable, at times life-threatening, and often necessitate cessation of therapy. At the same time, the rate of irAEs has been reported to be associated with superior response to ICIs for several cancer types. The precise causal relationship between irAEs and the ICI-elicited anti-tumour response remains poorly understood. Recent studies have detected identical TCR sequences that are shared between tumour and irAE-affected tissues from the same patient. Based on these findings, we hypothesize that ICIs can mobilize T cells which react to both tumour and normal tissue, contributing simultaneously to anti-tumour immunity and autoimmune pathology. To test this hypothesis, we will interrogate the phenotypes, TCR sequences, and antigen specificities of T cells that infiltrate skin irAE and tumour tissues of ICI-treated melanoma patients. Our work will shed light on how irAEs might be extricable from the anti-tumour efficacy of ICIs, potentially informing improved strategies to optimize the trade-off between therapeutic effect and collateral tissue damage.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
Missouri, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
474218
Name
Yao Jing Yuan
Region
Missouri
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the basis of immune-related adverse events caused by checkpoint inhibitor immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Immune Tolerance; Immunotherapy; Melanoma; T Cell Receptor; Tumour Antigens
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, achieving remarkably durable responses in a subset of patients. By blocking various cell surface molecules that inhibit immune cell function, ICIs potentiate tumour-reactive T cells to target neoplastic cells for elimination. Certain T cell receptors (TCRs) enable the specific recognition of tumour antigens, which encompass both self-derived antigens that can also be present in normal host tissues, as well as mutation-derived neoantigens that are seen as foreign by the immune system. While self-reactive T cells are typically restrained by immune tolerance mechanisms to avoid autoimmunity, these pathways can be obstructed by ICI-mediated disruption of inhibitory signals. Attesting to this breakdown in tolerance is the observation that patients treated with ICIs commonly experience immune-related adverse events (irAEs). These toxicities are unpredictable, at times life-threatening, and often necessitate cessation of therapy. At the same time, the rate of irAEs has been reported to be associated with superior response to ICIs for several cancer types. The precise causal relationship between irAEs and the ICI-elicited anti-tumour response remains poorly understood. Recent studies have detected identical TCR sequences that are shared between tumour and irAE-affected tissues from the same patient. Based on these findings, we hypothesize that ICIs can mobilize T cells which react to both tumour and normal tissue, contributing simultaneously to anti-tumour immunity and autoimmune pathology. To test this hypothesis, we will interrogate the phenotypes, TCR sequences, and antigen specificities of T cells that infiltrate skin irAE and tumour tissues of ICI-treated melanoma patients. Our work will shed light on how irAEs might be extricable from the anti-tumour efficacy of ICIs, potentially informing improved strategies to optimize the trade-off between therapeutic effect and collateral tissue damage.
Competitiondate
202210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yao, Jing Yuan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~